ALTAltimmune, Inc.

$331M

Q4 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-11.6% YoY

Gross Profit

-$1M-112.3% margin

Operating Income

-$6M-492.5% margin

Net Income

$78M6950.5% margin

EPS (Diluted)

$339.57

QoQ Revenue Growth

+12.6%

Cash Flow

Operating Cash Flow

$83M

Free Cash Flow

$83M

Stock-Based Comp.

$343,473

Balance Sheet

Total Assets

$225M

Total Liabilities

$205M

Stockholders' Equity

$19M

Cash & Equivalents

$154M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	-11.6%
Gross Profit	-$1M	-$277,667	-352.7%
Operating Income	-$6M	-$940,469	-486.1%
Net Income	$78M	-$1M	+6382.4%

ALT Q4 2016 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena